Anson Funds Management LP
- SEC CIK
- 0001491072
- Latest filing
- Aug 13, 2026
SPRO holding history
Spero Therapeutics, Inc. in every 13F filed by Anson Funds Management LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SPRO overviewAll 13F holders of SPROFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 15
- Since Q3 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −421,956−100.0% | Sold out | Holders |
| Q1 2026 | 421,956 | $987.4K | 0.1% | −203,106−32.5% | Reduced | Holders |
| Q4 2025 | 625,062 | $1.46M | 0.2% | −978,507−61.0% | Reduced | Holders |
| Q3 2025 | 1,603,569 | $3.01M | 0.3% | −11,900−0.7% | Reduced | Holders |
| Q2 2025 | 1,615,469 | $4.68M | 0.9% | −2,183,463−57.5% | Reduced | Holders |
| Q1 2025 | 3,798,932 | $2.74M | 0.7% | −40,954−1.1% | Reduced | Holders |
| Q4 2024 | 3,839,886 | $3.96M | 0.5% | +89,436+2.4% | Added | Holders |
| Q3 2024 | 3,750,450 | $5.03M | 0.7% | 00.0% | Unchanged | Holders |
| Q2 2024 | 3,750,450 | $4.88M | 0.7% | 00.0% | Unchanged | Holders |
| Q1 2024 | 3,750,450 | $6.45M | 0.5% | −547,249−12.7% | Reduced | Holders |
| Q4 2023 | 4,297,699 | $6.32M | 1.3% | +138,127+3.3% | Added | Holders |
| Q3 2023 | 4,159,572 | $5.03M | 1.7% | +714,710+20.7% | Added | Holders |
| Q2 2023 | 3,444,862 | $5.00M | 1.5% | +100,000+3.0% | Added | Holders |
| Q1 2023 | 3,344,862 | $4.85M | 1.5% | +325,254+10.8% | Added | Holders |
| Q4 2022 | 3,019,608 | $5.22M | 1.7% | +1,545,736+104.9% | Added | Holders |
| Q3 2022 | 1,473,872 | $2.95M | 0.6% | +1,473,872 | New | Holders |